Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 2
2006 1
2008 2
2009 1
2010 1
2012 1
2014 1
2015 1
2016 1
2020 1
2021 3
2022 1
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB, Richards H, Pricop L, Ligozio G, Patekar M, Mpofu S; FUTURE 2 Study Group. McInnes IB, et al. Among authors: ligozio g. Lancet. 2015 Sep 19;386(9999):1137-46. doi: 10.1016/S0140-6736(15)61134-5. Epub 2015 Jun 28. Lancet. 2015. PMID: 26135703 Free article. Clinical Trial.
Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis.
Mease P, van der Heijde D, Kirkham B, Schett G, Orbai AM, Ritchlin C, Merola JF, Pricop L, James DA, Zhu X, Ligozio G. Mease P, et al. Among authors: ligozio g. Arthritis Res Ther. 2022 Dec 28;24(1):283. doi: 10.1186/s13075-022-02944-1. Arthritis Res Ther. 2022. PMID: 36578042 Free PMC article.
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5.
van der Heijde D, Mease PJ, Landewé RBM, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Zhu X, Ligozio G, Readie A, Mpofu S, Pricop L. van der Heijde D, et al. Among authors: ligozio g. Rheumatology (Oxford). 2020 Jun 1;59(6):1325-1334. doi: 10.1093/rheumatology/kez420. Rheumatology (Oxford). 2020. PMID: 31586420 Free PMC article. Clinical Trial.
Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis.
Mallon AM, Häring DA, Dahlke F, Aarden P, Afyouni S, Delbarre D, El Emam K, Ganjgahi H, Gardiner S, Kwok CH, West DM, Straiton E, Haemmerle S, Huffman A, Hofmann T, Kelly LJ, Krusche P, Laramee MC, Lheritier K, Ligozio G, Readie A, Santos L, Nichols TE, Branson J, Holmes C. Mallon AM, et al. Among authors: ligozio g. BMC Med Res Methodol. 2021 Nov 14;21(1):250. doi: 10.1186/s12874-021-01409-4. BMC Med Res Methodol. 2021. PMID: 34773974 Free PMC article.
16 results